CPRD StudyPrimary Care PASS Study
Abstract 270: Distribution of CHA2DS2-VASc Scores in Patients with Atrial Fibrillation Treated with Rivaroxaban in Primary vs. Secondary Care Settings
Since its incorporation in the European Society of Cardiology guidelines in 2010, the CHA2DS2-VASc score is widely used to characterise the risk of stroke in patients (pts) with atrial fibrillation (AF).
CPRD StudyPrimary Care PASS Study
Abstract 269: Assessment of Start Dose in Patients Prescribed Rivaroxaban for Atrial Fibrillation with Chronic Kidney Disease-Results from the ROSE Study
Rivaroxaban is used to treat patients with non-valvular AF for the prevention of stroke and systemic embolism.
CPRD StudyPrimary Care PASS Study
Abstract 268: Characteristics of Patients Started on a Reduced Dose of Rivaroxaban for Atrial Fibrillation – Results from the ROSE Study
Rivaroxaban is used to treat a range of conditions, including prevention of stroke and systemic embolism in patients with AF.
CPRD StudyPrimary Care PASS Study
Abstract 267: Incidence Of Major And Clinically-Relevant Non-Major Bleeding In Patients Prescribed Rivaroxaban: Results From The ROSE Study
The ROSE (Rivaroxaban Observational Safety Evaluation) Specialist Cohort Event Monitoring (SCEM) study was conducted to monitor the safety and use of rivaroxaban for Stroke Prevention in patients (pts) with non-valvular AF (SPAF) and the prevention and/or treatment of Deep Vein Thrombosis and/or Pulmonary Embolism (DVT/PE) in the secondary care setting in England and Wales.
CPRD StudyPrimary Care PASS Study
Abstract 266: Multi-Level Modelling To Investigate Factors Impacting Prescribing Variability
Prescribing guidelines influence treatment choice based on patient and healthcare system factors.
CPRD StudyPrimary Care PASS Study
Abstract 265: Risk Of Major And Clinically Relevant Non-Major (CRNM) Bleeding In Patients Prescribed Rivaroxaban In Primary Care In England
Clinical trials and observational studies have reported bleeding risk in patients taking rivaroxaban.
CPRD StudyPrimary Care PASS Study
Abstract 264: Utilisation and safety of asenapine in secondary care in the UK: Results from the Observational Safety Evaluation of Asenapine (OBSERVA) study
The OBSERVA specialist cohort event monitoring (SCEM) study, conducted in secondary care in the UK, formed part of an EU risk management plan to monitor the use and short-term safety of asenapine, licensed for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
CPRD StudyPrimary Care PASS Study
Abstract 263: Utilisation and Safety of Asenapine in Primary Care in England: Results from a PASS
Asenapine is approved in the EU for the treatment of manic episodes associated with bipolar I disorder in adults.
CPRD StudyPrimary Care PASS Study
Abstract 262: Passive Enhanced Safety Surveillance In Children Receiving Fluenz® Tetra Vaccination In England During The Early 2017-2018 Influenza Season.
Fluenz® Tetra is a quadrivalent, live attenuated, intranasal, influenza vaccine recommended for use in children aged 2 to 17 years vaccinated as part of the seasonal influenza immunisation campaign in the UK.
CPRD StudyPrimary Care PASS Study
Abstract 271: Impact analyses of EU pharmacovigilance interventions on public health burden
Adverse drug reactions (ADRs) account for 5% hospital admissions and 197,000 deaths each year, amounting to a societal cost of €79billion.